美国老年类风湿关节炎患者中Janus激酶抑制剂与生物改善病情抗风湿药的癌症风险
基于SEER-Medicare数据库2014—2019年的病例对照研究,纳入12463例首次癌症病例与38345例无癌对照,评估老年类风湿关节炎患者使用JAK抑制剂与生物DMARDs的癌症风险。JAK抑制剂暴露与总体癌症风险无关(校正OR 1.04,95%CI 0.87-1.26),但与肺癌风险升高相关(OR 1.40,95%CI 1.06-1.87)。
要点
- JAK抑制剂暴露与总体癌症风险无关(校正OR 1.04,95%CI 0.87-1.26)。
- JAK抑制剂与肺癌风险升高相关(OR 1.40,95%CI 1.06-1.87),男性及暴露>2年者更明显。
- 女性JAK抑制剂暴露与乳腺癌风险降低相关(OR 0.62,95%CI 0.39-0.97)。
核心结论
- 在老年类风湿关节炎患者中,中位暴露1.8年的JAK抑制剂使用与总体癌症风险升高无关,但肺癌风险升高,支持对吸烟者处方该类药物时保持临床谨慎。
- 需要进一步研究以理解JAK/STAT通路在癌症中的作用。
研究设计与样本
- 病例对照研究,数据来自美国SEER-Medicare数据库2014—2019年,纳入65岁及以上类风湿关节炎患者。
- 病例为SEER注册中心诊断的首次癌症患者(N=12463),对照为居住在SEER地区的无癌Medicare受益人(N=38345)。
- 通过处方索赔确定JAK抑制剂、肿瘤坏死因子抑制剂和其他生物DMARDs的暴露,采用逻辑回归估计校正比值比(OR)。
主要发现
- 1.9%的病例和2.0%的对照被处方过JAK抑制剂。
- 接受JAK抑制剂的患者中,有记录暴露的中位持续时间为1.8年。
- 总体癌症风险与JAK抑制剂暴露无关(校正OR 1.04,95%CI 0.87-1.26),与肿瘤坏死因子抑制剂暴露无关(0.98,0.92-1.05),与其他生物DMARDs暴露无关(0.98,0.90-1.07)。
- JAK抑制剂暴露与肺癌风险显著升高相关(OR 1.40,95%CI 1.06-1.87),在男性中为(2.12,1.14-3.94),在JAK抑制剂暴露>2年者为(1.52,1.01-2.28)。
- 在女性中,JAK抑制剂暴露与乳腺癌风险降低相关(OR 0.62,95%CI 0.39-0.97)。
临床怎么用
- 作者认为,肺癌风险升高支持对吸烟者处方JAK抑制剂时保持临床谨慎。
- 作者指出需要进一步研究以理解JAK/STAT通路在癌症中的作用。
局限性
- 需要进一步研究以理解JAK/STAT通路在癌症中的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine cancer risk associated with Janus kinase inhibitors (JAKis) and biological DMARDs (bDMARDs) in patients with RA. METHODS: Case-control study of patients with RA age 65 years or older in the US Surveillance, Epidemiology, and End Results (SEER)-Medicare database during 2014-2019. Cases were individuals with a first cancer diagnosed in SEER registries (N = 12 463). Cancer-free controls (N = 38 345) were Medicare beneficiaries residing in SEER areas. Exposure to JAKis, tumour necrosis factor inhibitors (TNFis) and other bDMARDs was ascertained using prescription claims. Logistic regression was used to estimate adjusted odds ratios (ORs). RESULTS: 1.9% of cases and 2.0% of controls were prescribed a JAKi. Among patients prescribed a JAKi, the median duration of documented exposure was 1.8 years. Overall cancer risk was not associated with exposure to JAKis (adjusted OR 1.04, 95% CI 0.87-1.26), TNFis (0.98, 0.92-1.05) or other bDMARDs (0.98, 0.90-1.07). However, JAKi exposure was associated with significantly increased risk of lung cancer (OR 1.40, 95% CI 1.06-1.87), especially in males (2.12, 1.14-3.94) and with >2 years of JAKi exposure (1.52, 1.01-2.28). Among females, JAKi exposure was associated with lower risk of breast cancer (OR 0.62, 95% CI 0.39-0.97). CONCLUSIONS: Among older adults with RA, JAKi exposure over a median of 1.8 years was not associated with an overall increase in cancer risk. However, lung cancer risk was elevated, supporting clinical caution in prescribing this medication class to smokers. Further research is needed to understand the role of the JAK/STAT pathway in cancer.
引用
- Ahmed S, Pfeiffer RM, Jackson SS, et al. Cancer risk of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs among older Americans with rheumatoid arthritis. Rheumatology (Oxford). 2025. PMID: 39928358. doi:10.1093/rheumatology/keaf092
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。